The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms.

Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.

Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D- ...

Granulocyte colony-stimulating factor (G-CSF

Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

PURPOSE: A composition for treating ophthalmic diseases is provided to be conveniently applied in an eye drop or injection type and to treat various ophthalmic diseases related to angiogenesis and neo-lymphagiogenesis. CONSTITUTION: A sulindac liposome formulation for suppressing angiogenesis and neo-lymphagiogenesis contains sulindac and liposome. The liposome is formed of endoplasmic reticulum (ER)-forming lipid containing a hydrophobic portion of one or two hydrophobic acyl hydrocarbon chains...

Compositions and methods described herein are based on the use of the drug sulindac a non steroidal anti-inflammatory drug (NSAID) for protecting retinal pigment epithelial cells against oxidative stress which is a major component of macular degeneration. Described herein is a new use for sulindac.